Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
50.94
+0.28 (+0.55%)
4:03:13 PM EDT: $50.94 0.00 (0.00%)
Products, Equity Investments, Earnings Announcements

Valneva, Pfizer Finalise Equity Investment

Published: 06/23/2022 16:02 GMT
Pfizer Inc. (PFE) - Valneva and Pfizer Announce Closing of Equity Investment.
Pfizer Has Invested EUR 90.5 ($95) Million in Valneva, Representing 8.1% of Valneva's Share Capital at a Price of EUR 9.49 per Share, Through a Reserved Capital Increase.
Pfizer Plans to Initiate Phase 3 Study of Vla15 in Q3 of 2022.
Valneva is Planning to Use Proceeds to Support Its Contribution to Planned Phase 3 Development Program for Lyme Disease Vaccine Candidate Vla15.
Revenue is expected to be $25.45 Billion
Adjusted EPS is expected to be $1.79

Next Quarter Revenue Guidance is expected to be $25.56 Billion
Next Quarter EPS Guidance is expected to be $1.89

More details on our Analysts Page.